Regulation of intestinal chylomicron production by glucagon-like peptides

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 12, Issue 2, 2012, Pages 92-97

  Hsieh, Joanne ^a   Adeli, Khosrow ^a  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Apolipoprotein B48; Insulin resistance; Postprandial dyslipidemia

Indexed keywords

APOLIPOPROTEIN B48; CHYLOMICRON; EXENDIN 4; FATTY ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; N OLEOYLETHANOLAMINE; SITAGLIPTIN; TRIACYLGLYCEROL;

DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; INTESTINE CELL; LIPOGENESIS; LIPOLYSIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

ANIMALS; CHYLOMICRONS; GLUCAGON-LIKE PEPTIDES; HUMANS; INTESTINES;

EID: 84874872347     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X11202020092     Document Type: Review

References (68)

1. Zilversmit, D.B. Atherogenesis: a postprandial phenomenon. Circulation, 1979, 60(3), 473-485.
2. Redgrave, T.G. Chylomicron metabolism. Biochem.Soc.Trans., 2004, 32(Pt 1), 79-82.
3. Mero, N.; Syvanne, M.; Taskinen, M.R. Postprandial lipid metabolism in diabetes. Atherosclerosis, 1998, 141(1), S53-S55.
4. Curtin, A.; Deegan, P.; Owens, D.; Collins, P.; Johnson, A.; Tomkin, G.H. Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol., 1996, 33(3), 205-210.
5. Lewis, G.F.; O'Meara, N. M.; Soltys, P.A.; Blackman, J.D.; Iverius, P.H.; Druetzler, A. F.; Getz, G.S.; Polonsky, K.S. ostprandial lipoprotein metabolism in normal and obese subjects: comparison after the vitamin A fat-loading test. J. Clin. Endocrinol. Metab., 1990, 71(4), 1041-1050.
6. Chen, Y.D.; Swami, S.; Skowronski, R.; Coulston, A.; Reaven, G.M. Differences in postprandial lipemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab., 1993, 76(1), 172-177.
7. Rivellese, A.A.; De Natale, C.; Di Marino, L.; Patti, L.; Iovine, C.; Coppola, S.; Del Prato, S.; Riccardi, G.; Annuzzi, G. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J. Clin. Endocrinol. Metab., 2004, 89(5), 2153-2159.
8. Duez, H.; Lamarche, B.; Uffelman, K.D.; Valero, R.; Cohn, J.S.; Lewis, G.F. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol., 2006, 26(6), 1357-1363.
9. Annuzzi, G.; De Natale, C.; Iovine, C.; Patti, L.; Di Marino, L.; Coppola, S.; Del Prato, S.; Riccardi, G.; Rivellese, A.A. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol., 2004, 24(12), 2397-2402.
10. Taghibiglou, C.; Carpentier, A.; Van Iderstine, S.C.; Chen, B.; Rudy, D.; Aiton, A.; Lewis, G.F.; Adeli, K. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J. Biol. Chem., 2000, 275(12), 8416-8425.
11. Haidari, M.; Leung, N.; Mahbub, F.; Uffelman, K.D.; Kohen-Avramoglu, R.; Lewis, G. F.; Adeli, K. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J. Biol. Chem., 2002, 277(35), 31646-31655.
12. Lewis, G.F.; Uffelman, K.; Naples, M.; Szeto, L.; Haidari, M.; Adeli, K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology, 2005, 146(1), 247-255.
13. Federico, L.M.; Naples, M.; Taylor, D.; Adeli, K. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes, 2006, 55(5), 1316-1326.
14. Casaschi, A.; Maiyoh, G.K.; Adeli, K.; Theriault, A.G. Increased diacylglycerol acyltransferase activity is associated with triglyceride accumulation in tissues of diet-induced insulin-resistant hyperlipidemic hamsters. Metabolism, 2005, 54(3), 403-409.
15. Wong, D.M.; Webb, J.P.; Malinowski, P.M.; Xu, E.; Macri, J.; Adeli, K. Proteomic profiling of intestinal prechylomicron transport vesicle (PCTV)-associated proteins in an animal model of insulin resistance (94 char). J. Proteomics, 2010, 73(7), 1291-1305.
16. Zoltowska, M.; Ziv, E.; Delvin, E.; Sinnett, D.; Kalman, R.; Garofalo, C.; Seidman, E.; Levy, E. Cellular aspects of intestinal lipoprotein assembly in Psammomys obesus: a model of insulin resistance and type 2 diabetes. Diabetes, 2003, 52(10), 2539-2545.
17. Phillips, C.; Owens, D.; Collins, P.; Tomkin, G.H. Microsomal triglyceride transfer protein: does insulin resistance play a role in the regulation of chylomicron assembly? Atherosclerosis, 2002, 160(2), 355-360.
18. Mangat, R.; Su, J.; Scott, P.G.; Russell, J.C.; Vine, D. F.; Proctor, S.D. Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Biochem. Soc. Trans., 2007, 35(Pt 3), 477-481.
19. Petit, V.; Arnould, L.; Martin, P.; Monnot, M.C.; Pineau, T.; Besnard, P.; Niot, I. Chronic high-fat diet affects intestinal fat absorption and postprandial triglyceride levels in the mouse. J. Lipid Res., 2007, 48(2), 278-287.
20. Xie, Y.; Nassir, F.; Luo, J.; Buhman, K.; Davidson, N.O. Intestinal lipoprotein assembly in apobec-1-/-mice reveals subtle alterations in triglyceride secretion coupled with a shift to larger lipoproteins. Am. J. Physiol. Gastrointest. Liver Physiol., 2003, 285(4), G735-G746.
21. Kalogeris, T.J.; Rodriguez, M.D.; Tso, P. Control of synthesis and secretion of intestinal apolipoprotein A-IV by lipid. J. Nutr., 1997, 127(3), 537S-543S.
22. Hussain, M.M.; Nijstad, N.; Franceschini, L. Regulation of microsomal triglyceride transfer protein. Clin. Lipidol., 2011, 6(3), 293-303.
23. Cao, J.; Hawkins, E.; Brozinick, J.; Liu, X.; Zhang, H.; Burn, P.; Shi, Y. A predominant role of acyl-CoA:monoacylglycerol acyltransferase-2 in dietary fat absorption implicated by tissue distribution, subcellular localization, and up-regulation by high fat diet. J. Biol. Chem., 2004, 279(18), 18878-18886.
24. Hernandez Vallejo, S. J.; Alqub, M.; Luquet, S.; Cruciani-Guglielmacci, C.; Delerive, P.; Lobaccaro, J. M.; Kalopissis, A. D.; Chambaz, J.; Rousset, M.; Lacorte, J. M. Short-term adaptation of postprandial lipoprotein secretion and intestinal gene expression to a high-fat diet. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296(4), G782-G792.
25. Young, N.L.; Saudek, C.D.; Walters, L.; Lapeyrolerie, J.; Chang, V. Preventing hyperphagia normalizes 3-hydroxy-3-methylglutaryl-CoA reductase activity in small intestine and liver of diabetic rats. J. Lipid Res., 1982, 23(6), 831-838.
26. Herrmann, C.; Goke, R.; Richter, G.; Fehmann, H.C.; Arnold, R.; Goke, B. Glucagon-like peptide-1 and glucose-dependent insulinreleasing polypeptide plasma levels in response to nutrients. Digestion, 1995, 56(2), 117-126.
27. Xiao, Q.; Boushey, R.P.; Drucker, D.J.; Brubaker, P.L. Gastroenterology, 1999, 117(1), 99-105.
28. Iakoubov, R.; Ahmed, A.; Lauffer, L.M.; Bazinet, R.P.; Brubaker, P.L. Essential role for protein kinase C in oleic acid-induced glucagon-like peptide-1 secretion in vivo in the rat. Endocrinology, 2011, 152(4), 1244-1252.
29. Thomsen, C.; Rasmussen, O.; Lousen, T.; Holst, J.J.; Fenselau, S.; Schrezenmeir, J.; Hermansen, K. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am. J. Clin. Nutr., 1999, 69(6), 1135-1143.
30. Beysen, C.; Karpe, F.; Fielding, B.A.; Clark, A.; Levy, J.C.; Frayn, K.N. Interaction between specific fatty acids, GLP-1 and insulin secretion in humans. Diabetologia, 2002, 45(11), 1533-1541.
31. Rocca, A.S.; LaGreca, J.; Kalitsky, J.; Brubaker, P.L. Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1. Endocrinology, 2001, 142(3), 1148-1155.
32. Edfalk, S.; Steneberg, P.; Edlund, H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008, 57(9), 2280-2287.
33. Hsieh, J.; Longuet, C.; Maida, A.; Bahrami, J.; Xu, E.; Baker, C.L.; Brubaker, P.L.; Drucker, D.J.; Adeli, K. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology, 2009, 137(3), 997-1005, 1005.
34. Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; Miyazaki, S.; Tsujimoto, G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med., 2005, 11(1), 90-94.
35. Oh, D.Y.; Talukdar, S.; Bae, E.J.; Imamura, T.; Morinaga, H.; Fan, W.; Li, P.; Lu, W.J.; Watkins, S.M.; Olefsky, J.M. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell, 2010, 142(5), 687-698.
36. Schwartz, G.J.; Fu, J.; Astarita, G.; Li, X.; Gaetani, S.; Campolongo, P.; Cuomo, V.; Piomelli, D. The lipid messenger OEA links dietary fat intake to satiety. Cell Metab., 2008, 8(4), 281-288.
37. Lauffer, L.M.; Iakoubov, R.; Brubaker, P.L. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes, 2009, 58(5), 1058-1066.
38. Iakoubov, R.; Izzo, A.; Yeung, A.; Whiteside, C.I.; Brubaker, P.L. Protein kinase Czeta is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells. Endocrinology, 2007, 148(3), 1089-1098.
39. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.; Mataki, C.; Pruzanski, M.; Pellicciari, R.; Auwerx, J.; Schoonjans, K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab., 2009, 10(3), 167-177.
40. Lim, G.E.; Huang, G.J.; Flora, N.; LeRoith, D.; Rhodes, C.; Brubaker, P.L. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology, 2009, 150(2), 580-591.
41. Anini, Y.; Brubaker, P.L. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes, 2003, 52(2), 252-259.
42. Ellingsgaard, H.; Hauselmann, I.; Schuler, B.; Habib, A. M.; Baggio, L.L.; Meier, D.T.; Eppler, E.; Bouzakri, K.; Wueest, S.; Muller, Y.D.; Hansen, A.M.; Reinecke, M.; Konrad, D.; Gassmann, M.; Reimann, F.; Halban, P.A.; Gromada, J.; Drucker, D. J.; Gribble, F.M.; Ehses, J.A.; Donath, M.Y. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med., 2011, 17(11), 1481-1489.
43. Reimer, R.A.; Russell, J.C. Glucose tolerance, lipids, and GLP-1 secretion in JCR:LA-cp rats fed a high protein fiber diet. Obesity(Silver.Spring), 2008, 16(1), 40-46.
44. Gniuli, D.; Calcagno, A.; Dalla, L.L.; Calvani, R.; Leccesi, L.; Caristo, M.E.; Vettor, R.; Castagneto, M.; Ghirlanda, G.; Mingrone, G. High-fat feeding stimulates endocrine, glucosedependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats. Diabetologia, 2010, 53(10), 2233-2240.
45. Muscelli, E.; Mari, A.; Casolaro, A.; Camastra, S.; Seghieri, G.; Gastaldelli, A.; Holst, J. J.; Ferrannini, E. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes, 2008, 57(5), 1340-1348.
46. Toft-Nielsen, M.B.; Damholt, M.B.; Madsbad, S.; Hilsted, L.M.; Hughes, T.E.; Michelsen, B.K.; Holst, J.J. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab., 2001, 86(8), 3717-3723.
47. Vilsboll, T.; Krarup, T.; Deacon, C.F.; Madsbad, S.; Holst, J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 2001, 50(3), 609-613.
48. Ranganath, L.R.; Beety, J.M.; Morgan, L.M.; Wright, J.W.; Howland, R.; Marks, V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut, 1996, 38(6), 916-919.
49. Rask, E.; Olsson, T.; Soderberg, S.; Johnson, O.; Seckl, J.; Holst, J.J.; Ahren, B. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care, 2001, 24(9), 1640-1645.
50. Rask, E.; Olsson, T.; Soderberg, S.; Holst, J.J.; Tura, A.; Pacini, G.; Ahren, B. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. Metabolism, 2004, 53(5), 624-631.
51. Lugari, R.; Dei, C.A.; Ugolotti, D.; Finardi, L.; Barilli, A.L.; Ognibene, C.; Luciani, A.; Zandomeneghi, R.; Gnudi, A. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm. Metab Res., 2002, 34(3), 150-154.
52. Meier, J.J.; Gethmann, A.; Gotze, O.; Gallwitz, B.; Holst, J.J.; Schmidt, W.E.; Nauck, M.A. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia, 2006, 49(3), 452-458.
53. Duez, H.; Lamarche, B.; Valero, R.; Pavlic, M.; Proctor, S.; Xiao, C.; Szeto, L.; Patterson, B.W.; Lewis, G.F. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation, 2008, 117(18), 2369-2376.
54. Guo, Q.; Avramoglu, R.K.; Adeli, K. Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids. Metabolism, 2005, 54(5), 689-697.
55. Lewis, G. F.; Naples, M.; Uffelman, K.; Leung, N.; Szeto, L.; Adeli, K. Intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids in the fasting state: studies in insulin-resistant and insulin-sensitized Syrian golden hamsters. Endocrinology, 2004, 145(11), 5006-5012.
56. Schwartz, S.L.; Ratner, R.E.; Kim, D.D.; Qu, Y.; Fechner, L.L.; Lenox, S.M.; Holcombe, J.H. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin. Ther., 2008, 30(5), 858-867.
57. Qin, X.; Shen, H.; Liu, M.; Yang, Q.; Zheng, S.; Sabo, M.; D'Alessio, D.A.; Tso, P. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am. J. Physiol Gastrointest. Liver Physiol., 2005, 288(5), G943-G949.
58. Hsieh, J.; Longuet, C.; Baker, C.L.; Qin, B.; Federico, L.M.; Drucker, D.J.; Adeli, K. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia, 2010, 53(3), 552-561.
59. DeFronzo, R.A.; Okerson, T.; Viswanathan, P.; Guan, X.; Holcombe, J.H.; MacConell, L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr. Med. Res. Opin., 2008, 24(10), 2943-2952.
60. Matikainen, N.; Manttari, S.; Schweizer, A.; Ulvestad, A.; Mills, D.; Dunning, B.E.; Foley, J.E.; Taskinen, M.R. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006, 49(9), 2049-2057.
61. Pavlic, M.; Xiao, C.; Szeto, L.; Patterson, B.W.; Lewis, G.F. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes, 2010, 59(3), 580-587.
62. Schwartz, E.A.; Koska, J.; Mullin, M.P.; Syoufi, I.; Schwenke, D.C.; Reaven, P.D. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis, 2010, 212(1), 217-222.
63. Xiao, C.; Bandsma, R.H.; Dash, S.; Szeto, L.; Lewis, G.F. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler.Thromb.Vasc.Biol., 2012, 32(6),1513-9.
64. Pederson, R.A.; Satkunarajah, M.; McIntosh, C.H.; Scrocchi, L.A.; Flamez, D.; Schuit, F.; Drucker, D.J.; Wheeler, M.B. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor-/-mice. Diabetes, 1998, 47(7), 1046-1052.
65. Brubaker, P.L.; Izzo, A.; Hill, M.; Drucker, D.J. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am. J. Physiol., 1997, 272(6 Pt 1), E1050-E1058.
66. Meier, J.J.; Nauck, M.A.; Pott, A.; Heinze, K.; Goetze, O.; Bulut, K.; Schmidt, W.E.; Gallwitz, B.; Holst, J.J. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology, 2006, 130(1), 44-54.
67. Xiao, C.; Pavlic, M.; Szeto, L.; Patterson, B.W.; Lewis, G.F. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes, 2011, 60(2), 383-390.
68. Hein, G. J.; Baker, C. L.; Hsieh, J.; Adeli, K. Diabetes 2011, 60(1), 0682-P.